Literature DB >> 10702341

A simple and rapid evaluation of methemoglobin toxicity of 8-aminoquinolines and related compounds.

P Srivastava1, S Singh, G K Jain, S K Puri, V C Pandey.   

Abstract

Methemoglobin, a toxic ferric form of hemoglobin, is continuously formed in normal erythrocytes, but during abnormal situations in situ, the level is enhanced. 8-Amino-quinolines and related compounds are causative agents for methemoglobin formation. Employing oxyhemoglobin, methemoglobin toxicity was about six times higher with primaquine compared to CDRI Compound 80/53 at 10(-9) M concentration. Methemoglobin reductase activity was also completely inhibited by primaquine, whereas 24% inhibition was noted in the case of 80/53 at the same concentrations. Mastomys, a rodent animal model, was found to be equally good for comparative evaluation of methemoglobin toxicity. Further, with the use of primaquine transdermal tape on the Mastomys model, a rise in methemoglobin occurred with increase in time. In conclusion, the study presents simple, economical, less time-consuming methods for the evaluation of methemoglobin toxicity, in vitro and in vivo, without employing the conventional Beagle dog model. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702341     DOI: 10.1006/eesa.1999.1868

Source DB:  PubMed          Journal:  Ecotoxicol Environ Saf        ISSN: 0147-6513            Impact factor:   6.291


  8 in total

1.  Synthesis, antiprotozoal, antimicrobial, β-hematin inhibition, cytotoxicity and methemoglobin (MetHb) formation activities of bis(8-aminoquinolines).

Authors:  Kirandeep Kaur; Meenakshi Jain; Shabana I Khan; Melissa R Jacob; Babu L Tekwani; Savita Singh; Prati Pal Singh; Rahul Jain
Journal:  Bioorg Med Chem       Date:  2010-11-25       Impact factor: 3.641

2.  DFT study on the radical anions formed by primaquine and its derivatives.

Authors:  Haining Liu; Larry A Walker; Robert J Doerksen
Journal:  Chem Res Toxicol       Date:  2011-07-07       Impact factor: 3.739

3.  Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.

Authors:  Ann K Miller; Emma Harrell; Li Ye; Sharon Baptiste-Brown; Jőrg-Peter Kleim; Colin Ohrt; Stephan Duparc; Jörg J Möhrle; Alison Webster; Sandra Stinnett; Arlene Hughes; Sandy Griffith; Andrew P Beelen
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

4.  Effect of antimalarial drug primaquine and its derivatives on the ionization potential of hemoglobin: A QM/MM study.

Authors:  Haining Liu; Yuanqing Ding; Larry A Walker; Robert J Doerksen
Journal:  Medchemcomm       Date:  2013-08-01       Impact factor: 3.597

5.  Synthesis and evaluation of naphthyridine compounds as antimalarial agents.

Authors:  Shuren Zhu; Quan Zhang; Chandrashekar Gudise; Li Meng; Lai Wei; Erika Smith; Yuliang Kong
Journal:  Bioorg Med Chem Lett       Date:  2007-09-15       Impact factor: 2.823

6.  Imidazoquines as antimalarial and antipneumocystis agents.

Authors:  Nuno Vale; Miguel Prudêncio; Catarina A Marques; Margaret S Collins; Jiri Gut; Fátima Nogueira; Joana Matos; Philip J Rosenthal; Melanie T Cushion; Virgílio E do Rosário; Maria M Mota; Rui Moreira; Paula Gomes
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

7.  Hydroxylated derivatives of NPC1161: theoretical insights into their potential toxicity and the feasibility and regioselectivity of their formation.

Authors:  Yuanqing Ding; Haining Liu; N P Dhammika Nanayakkara; Ikhlas A Khan; Babu L Tekwani; Larry A Walker; Robert J Doerksen
Journal:  J Phys Chem A       Date:  2014-07-11       Impact factor: 2.781

8.  Computational Study on the Effect of Exocyclic Substituents on the Ionization Potential of Primaquine: Insights into the Design of Primaquine-Based Antimalarial Drugs with Less Methemoglobin Generation.

Authors:  Haining Liu; Yuanqing Ding; Larry A Walker; Robert J Doerksen
Journal:  Chem Res Toxicol       Date:  2015-01-27       Impact factor: 3.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.